Therefore, SIRT1 may be a therapeutic target for inhibiting cancer metastasis driven by Ang II, and PPD may be an alternative candidate for developing combined targeted therapies antagonistic to Ang II in NSCLC. This evidence concerns the gene AGT and cancer.